Cumberland Pharmaceuticals Inc. (CPIX) AI Stock Analysis
CPIX AI stock analysis summary
AI ResearchCumberland Pharmaceuticals Inc. (CPIX) is a specialty pharmaceutical company focused on prescription products for hospital acute care, gastroenterology, and oncology. In FY2025, revenue increased 17.6% to $44.5M, while net income was -$2.8M. Over the trailing twelve months ended June 30, 2026, revenue stood at $44.3M, accompanied by a quarterly revenue growth decline of 56.3% year-over-year.
- Market cap
- $107.6M
- Revenue (TTM)
- $44.3M
- P/E
- — fwd 50.0x
- 1Y return
- 240.1% S&P 500 16.8%
- Avg. target
- $8.50 18.4% vs last close
Bull case
- Gross margin expanded from 75.5% in FY2021 to 85.0% in FY2025.
- The business generated positive free cash flow of $4.8M and operating cash flow of $4.9M in FY2025.
- The stock delivered a 1-year return of 240.1%, outperforming the S&P 500 return of 16.8%.
Bear case
- Quarterly revenue growth dropped 56.3% year-over-year in the quarter ended June 30, 2026.
- The stock trades at a forward P/E of 50.0x, above the median of its US-listed Healthcare peers of 17.3x.
- The company has reported annual net losses across all recent periods, including -$2.8M in FY2025.
What Cumberland Pharmaceuticals does
Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company that acquires, develops, and commercializes prescription products for hospital acute care, gastroenterology, rheumatology, and oncology in the United States and internationally. Its portfolio includes Acetadote for acetaminophen poisoning, Caldolor for pain and fever, Kristalose for constipation, Omeclamox-Pak for Helicobacter pylori infection, Vaprisol for hyponatremia, and Vibativ for serious bacterial infections. In addition, the company develops RediTrex for arthritis and psoriasis and is advancing ifetroban in clinical trials for conditions such as respiratory disease and muscular dystrophy.
Growth and profitability
From FY2020 to FY2025, Cumberland Pharmaceuticals registered a five-year revenue CAGR of 3.5%. Revenue was $36.0M in FY2021, $42.0M in FY2022, $39.6M in FY2023, and $37.9M in FY2024 before increasing 17.6% to $44.5M in FY2025. Gross margin expanded from 75.5% in FY2021 to 85.0% in FY2025, while operating margin improved from -21.3% to -6.3%. Annual net losses narrowed from -$3.5M in FY2021 and -$6.5M in FY2024 to -$2.8M in FY2025. For the trailing twelve months ended June 30, 2026, revenue was $44.3M with an operating margin of -1898.6%, and quarterly revenue growth fell 56.3% year-over-year.
Balance sheet and cash flow
As of June 30, 2026, Cumberland Pharmaceuticals held $3.9M in cash and short-term investments against total debt of $4.7M, resulting in net debt of $851,782. Shareholders' equity was $17.4M, total assets were $62.9M, the current ratio was 0.96, and the debt-to-equity ratio was 0.27. In FY2025, the company generated $4.9M in operating cash flow and $4.8M in free cash flow. Capital deployment in FY2025 included $97,902 in capital expenditures and $263,478 in share buybacks.
Valuation and performance
With a market capitalization of $107.6M and an enterprise value of $105.4M, Cumberland Pharmaceuticals trades at a forward P/E of 50.0x and an EV to EBITDA of 40.9x. These levels compare to the median of its US-listed Healthcare peers of 17.3x forward P/E and 12.0x EV to EBITDA. CPIX trades at a price-to-sales multiple of 2.4x against the peer median of 4.1x. Over the past year, the stock gained 240.1%, outperforming the S&P 500 return of 16.8%.
What analysts expect
Analysts have set a mean price target of $8.50 for Cumberland Pharmaceuticals, indicating an 18.4% upside relative to its last close of $7.18 on October 16, 2026. The company has posted 0 EPS beats over the last 4 quarters. The next earnings date is scheduled for November 3, 2026. Insider ownership stands at 41.6%, while institutional investors hold 16.6% and short interest is 4.0% of the float.
Key risks and what to watch
- Operating margin was -1898.6% for the trailing twelve months, reflecting significant operating cost burdens.
- The current ratio stood at 0.96 as of June 30, 2026, indicating short-term obligations exceed current assets.
- The company achieved 0 EPS beats over the last 4 quarters heading into its November 3, 2026 earnings date.
- CPIX trades 73.3% above its 200-day average, leaving it exposed to pullbacks toward its 52-week low of $1.85.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this CPIX AI stock analysis
This page is an AI-written research summary of Cumberland Pharmaceuticals Inc. (CPIX). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: CPIX income statement, CPIX balance sheet, CPIX key metrics, CPIX chart. See the CPIX stock overview for the latest quote and news.
CPIX AI stock analysis FAQ
What is Cumberland Pharmaceuticals' ticker and exchange?
Cumberland Pharmaceuticals trades on the NASDAQ under the ticker symbol CPIX.
Does Cumberland Pharmaceuticals pay a dividend?
No, Cumberland Pharmaceuticals does not pay a dividend.
What is the analyst price target for CPIX?
The mean analyst price target is $8.50, which represents an 18.4% upside from the October 16, 2026 closing price of $7.18.
What were Cumberland Pharmaceuticals' FY2025 revenue and cash flow?
In FY2025, revenue was $44.5M, operating cash flow was $4.9M, and free cash flow was $4.8M.
When is Cumberland Pharmaceuticals' next earnings report?
The company's next earnings report date is November 3, 2026.